RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Theralase on Global TVThanks CancerSlayer
I agree that no competitor trial currently ongoing that I am aware of is comparable and in my opinion this company (TLT) is a minimum of 10 years ahead of all others if not decades! Although this company (TLT) is extremely exciting I would like to see hard numbers before calling them the first place winner.
CancerSlayer wrote
Well said Apohpis...& US PIs will likely have 5-10X the patient base compared to the Canadian sites. Moreover, we should draw significant interest in the US simply based on the fact that PDT is more established & may be perceived as a more acceptable option.
I also like the fact that there is no competitor trial "anywhere" that offers both a unique & promising type of treatment. In terms of other competitor trials, Keytruda is over & done with (boasting only marginal results ) & our next closest competitor (Anktiva aka N-803...used in combo with BCG) is further along in their Ph 2/3 trial. Interestingly, Roswell Park is a designated trial site for this drug.
As for Covid, fortunately, new case numbers are generally decreasing throughout North America. Also, patients in the US will not be treated in a higher-risk setting like a busy hospital/medical center, but rather at well-versed & well-protected ambulatory surgery centers. This pandemic is showing signs of weakening & I expect enrollment numbers are finally going to take off in the first half of this year...GLTA.